Target intelligence / Profile preview

Ubiquitin-specific peptidase 5 (USP5)

Target
USP5
Molecular classification
Enzyme, Deubiquitinating enzyme, Cysteine protease, Ubiquitin-specific protease
01

Overview

Ubiquitin-specific peptidase 5 (USP5), also known as isopeptidase T (IsoT), is a crucial deubiquitinating enzyme belonging to the ubiquitin-specific protease (USP) family. It plays a unique and essential role in maintaining cellular ubiquitin homeostasis by specifically recognizing and disassembling unanchored polyubiquitin chains into monoubiquitin. USP5 is highly implicated in various pathological conditions, particularly oncology, where its overexpression stabilizes key oncoproteins (such as SLUG, FOXM1, and beta-catenin) and promotes tumor cell proliferation, metastasis, and drug resistance. Additionally, USP5 is involved in the transmission of neuropathic and inflammatory pain signals by regulating T-type calcium channels (Cav3.2). Consequently, USP5 has emerged as an attractive therapeutic target, with several small-molecule inhibitors, such as WP1130, EOAI3402143, and vialinin A, being developed to block its catalytic activity or its zinc-finger ubiquitin-binding domain (ZnF-UBD). However, therapeutic targeting of USP5 presents challenges, as complete genetic knockout is embryonically lethal in mice, and systemic inhibition can lead to proteasome dysfunction due to the accumulation of free polyubiquitin chains.

Other names
Isopeptidase TIsoTUbiquitin carboxyl-terminal hydrolase 5Deubiquitinating enzyme 5Ubiquitin thioesterase 5Ubiquitin-specific-processing protease 5
02

Mechanism of action

Inhibition of deubiquitinating activity, leading to accumulation of unanchored polyubiquitin chains, proteasome inhibition, and stabilization of target proteins like p53 or degradation of oncoproteins.

03

Biological functions

DeubiquitinationProtein degradationDNA damage repairApoptosisImmune responseCell proliferationStress responsePain transmission
04

Disease associations

CancerInflammationNeuropathic painAutoimmune diseaseRheumatoid arthritis
05

Safety considerations

Embryonic lethality (homozygous knockout is lethal at embryonic day 7 in mice)Systemic proteasome inhibition due to accumulation of unanchored polyubiquitin chainsPotential for off-target effects due to structural similarity with other USPsDisruption of cellular ubiquitin homeostasis
06

Interacting drugs

6 more in the full profile.

07

Biomarkers

USP5 expression levelp53 accumulationMETTL14 levelsbeta-catenin levelsunanchored polyubiquitin chain accumulation

Beyond the preview

Go deeper on Ubiquitin-specific peptidase 5 (USP5).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ubiquitin-specific peptidase 5 (USP5).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call